



# fADL-1e Phage Vector fADL-1e Phage Vector

## INSTRUCTION MANUAL

---

fADL™-1e Phage Vector for Phage Display

Catalog #: PD020

Version: A1.5 – December 2022



---

## Table of Contents

Legal and Disclaimers	3
<b>Description</b>	
Introduction	4
Content, Shipping & Storage	4
Limited Product Warranty	4
Vector Map	5
Cloning Site	5
Feature Table	6
Restriction Site Summary	6
<b>Experimental Procedures</b>	
Working with fADL-1e	8
General Molecular Biology Techniques	8
Working with Filamentous Phage	8
Bacterial Strains	8
Plasmid Maintenance	8
Cloning into fADL-1e	9
Sequencing of Inserts	10
Counting & Amplifying fADL-1e Virions	10
Working with fADL-1e Virions	11
Biopanning	Error! Bookmark not defined.2
<b>Appendix</b>	
MSDS Information	13
Quality Control	13
Technical Support	13
References	13

---

## Legal and Disclaimers

**Antibody Design Labs** grants to the buyer with the sale of its phage and/or phagemid vectors (the “Product”) a non-exclusive, non-transferable, royalty-free, commercial license to use Product in research conducted by the buyer (whether the buyer is an academic or a for-profit entity). The buyer is NOT granted a license to (a) use Product for human or animal therapeutic, diagnostic, or prophylactic purposes, (b) act as reseller or distributor of Product, or (c) resell, distribute, or transfer Product without modification under any name. **Antibody Design Labs** does not warrant that the use or sale of Product, the use thereof in combination with other products, or the use of Product in the operation of any process will not infringe the claims of any United States or other patent(s). If the buyer is not willing to accept the limitations of this license, without modification, buyer may refuse this license by returning Product unopened and unused. By keeping or using Product, buyer agrees to be bound by the terms of this license.

---

# Description

## Introduction

---

The fADL™-1e vector is a type 3 phage display vector (Smith 1997) with a cloning site for display on the N-terminal side of the full-length gene III protein. Secretion in the periplasm of the fusion protein is driven by the PelB leader peptide, in place of the wild-type gene III protein leader sequence.

fADL™-1e derives from the phage vector fd-kan, a vector analogous to fd-tet (Smith 1990) where the tetracycline resistance genes derived from Tn10 have been replaced by the kanamycin resistance determinant of Tn903. It has a smaller size (7993 bp), making cloning easier. Like fd-tet, the number of double-stranded RF copy number is relatively low, about 60 copies in stationary-phase cells. Therefore fADL-1e is well tolerated by the host, giving large colonies and small plaques. Yield of physical particles is about  $5 \times 10^{11}$  virions/ml, similar to fd-tet; infectivity of the virions is around 5%, depending on the insert sequence. Display is usually multivalent with limited polyphage production, even in the case of large polypeptides such as scFvs.

fADL™-1e differs from fADL™-1 by the presence of an SpeI site in the cloning site and a G->A mutation in g8p sequence at position 1403 making the major coat protein VIII sequence identical to M13 protein VIII. This mutation improves cross-reactivity between M13 antibodies and fADL™ virions.

## Content, Shipping & Storage

---

### Content

VECTOR	COMPOSITION	AMOUNT
fADL™-1E	20 µl at 0.5 µg/µl of DNA vector in DNA Conservation Buffer (Tris-HCL 5 mM, EDTA 0.1 mM, pH 8.5)	10 µg

### Shipping & Storage

fADL™-1e phage vector is shipped on wet ice. Upon receipt, store the vector at -20°C.

## Limited Product Warranty


---

This warranty limits our liability to the replacement of this product. No other warranties of any kind express or implied, including, without limitation, implied warranties of merchantability or fitness for a particular purpose, are provided by Antibody Design Labs. Antibody Design Labs shall have no liability for any direct, indirect, consequential, or incidental damages arising out of the use, the results of use, or the inability to use this product.

*For research use only; not intended for any animal or human therapeutic or diagnostic use.*


## Vector Map

The figure below illustrates the main features of fADL™-1e vector. The full vector sequence is available online for download in varied formats on the product web page; the total length of the vector is 7993 bp.



## Cloning Site

Following is an illustration of fADL-1e cloning site from the end of the gene VIII sequence to the gene III sequence. The PelB peptide leader sequence (translation *MKYLLPTAAAGLLLLAAQPAMA*) is missing the two last amino acids MA, which will have to be re-introduced during cloning to insure proper reading frame and cleavage (on the C-terminal side of the terminal Alanine).



## Feature Table

The main features of fADL™-1e vector are highlighted in the following table.

FEATURE	LOCATION	DESCRIPTION
Protein VIII terminator	1538-1564	Transcriptional terminator.
PelB leader sequence	1586-1648	PelB leader sequence for export in the periplasm of the host bacteria. The missing terminal methionine and alanine will have to be added during the cloning to obtain a complete leader peptide (MKYLLPTAAAGLLLLAAQPAMA) necessary for proper removal of the leader during the export process.
g3p fusion coding sequence	1681-2901	Full-length gene III fusion protein coding sequence; the fd g3p protein is fused on its N-terminal side to the linker GPGGLSLE; the exact final sequence of the fusion depends on the cloning strategy (see cloning site).
Kan <sup>R</sup>	7100-6285	Kanamycin resistance gene

## Restriction Site Summary

Enzyme	Site	Nb	Position	Strand	Isoschizomers
AjuI	(7/12) GAANNNNNNNTTGG (11/6)	1	6620	-	
AloI	(7/12) GAACNNNNNNNTCC (12/7)	1	7351	-	
BalI	TGG^CCA	1	5129		MlsI MluNI Mox20I MscI Msp20I
BamHI	G^GATCC	1	2268		
BseRI	GAGGAG (10/8)	1	2056		
BspI407I	T^GTACA	1	1021		BsrGI BstAUI
BstAPI	GCANNNN^NTGC	1	6079		
BstEII	G^GTNACC	1	5712		BstPI Eco91I EcoO65I PspEI
CspCI	(11/13) CAANNNNNGTGG (12/10)	1	3058		
DrdI	GACNNNN^NNGTC	1	7345		AasI DseDI
EagI	C^GGCCG	1	1608		BseX3I BstZI EclXI Eco52I
EciI	GGCGGA (11/9)	1	2010	-	
Esp3I	CGTCTC (1/5)	1	6654	-	BsmBI
FalI	(8/13) AAGNNNNNCTT (13/8)	1	2534		
GsuI	CTGGAG (16/14)	1	7642	-	BpmI
KroI	G^CCGGC	1	1639		
NaeI	GCC^GGC	1	1639		PdiI NgoMIV MroNI
NotI	GC^GGCCGC	1	1607		CciNI
NruI	TCG^CGA	1	7009		Bsp68I BtuMI RruI
PacI	TTAAT^TAA	1	4181		
PflMI	CCANNNN^NTGG	1	6402		AccB7I Van91I
PshAI	GACNN^NNGTC	1	990		BoxI BstPAI
PspXI	VC^TCGAGB	1	7065		
PvuI	CGAT^CG	1	6667		Ple19I
SacII	CCGC^GG	1	6141		Sfr303I KspI SgrBI Cfr42I
SalI	G^TCGAC	1	1565		
SgfI	GCGAT^CGC	1	6666		AsiSI RgaI SfaAI
SnaBI	TAC^GTA	1	1268		BstSNI Eco105I
SpeI	A^CTAGT	1	1651		AhlI BcuI
StuI	AGG^CCT	1	1665		Eco147I PceI SseBI
SwaI	ATTT^AAAT	1	7526		SmiI

XbaI	T <sup>^</sup> CTAGA	1	1674	
XcmI	CCANNNNN <sup>^</sup> NNNNTGG	1	1644	
XhoI	C <sup>^</sup> TCGAG	1	7066	Sfr274I PaeR7I SlaI
AccI	AA <sup>^</sup> CGTT	2	4683	Psp1406I
		2	7516	
AlfI	(10/12)GCANNNNNNTGC(12/10)	2	4892	
		2	6988	
BaeI	(10/15)ACNNNNGTAYC(12/7)	2	1843	-
		2	2185	
BbvCI	CCTCAGC(-5/-2)	2	1370	-
		2	1416	
BglI	GCCNNNN <sup>^</sup> NGGC	2	1634	
		2	1658	
BsaXI	(9/12)ACNNNNNCTCC(10/7)	2	1939	
		2	7351	
BspMI	ACCTGC(4/8)	2	1113	-
		2	2306	Acc36I BfuAI BveI
BsrBI	CCGCTC(-3/-3)	2	4618	AccBSI MbiI
		2	5621	
BtsI	GCAGTG(2/0)	2	6723	-
		2	6802	
DraIII	CACNNN <sup>^</sup> GTG	2	7197	AdeI
		2	7302	
EarI	CTCTTC(1/4)	2	4123	Bst6I Eam1104I
		2	6857	
EcoNI	CCTNN <sup>^</sup> NNNAGG	2	2987	BstENI XagI
		2	6751	
EcoP15I	CAGCAG(25/27)	2	1368	-
		2	4921	
HindIII	A <sup>^</sup> AGCTT	2	6023	
		2	6546	
MfeI	C <sup>^</sup> AATTG	2	715	MunI
		2	5200	
PciI	A <sup>^</sup> CATGT	2	195	PscI
		2	3766	
PsiI	TTA <sup>^</sup> TAA	2	5772	AanI
		2	7430	
SfiI	GGCCNNNN <sup>^</sup> NGGCC	2	1633	
		2	1657	
SmaI	CCC <sup>^</sup> GGG	2	1659	Cfr9I TspMI XmaI
		2	6792	
XmnI	GAANN <sup>^</sup> NNTTC	2	357	Asp700I MroXI PdmI
		2	2694	

Absent Sites:

AarI, AatII, AbsI, AflIII, AgeI, ApaI, ApaLI, AscI, AsuII, AvrII, BarI, BbsI, BcgI, BciVI, BclI, BglIII, BlpI, BmrI, BplI, BsePI, BsgI, BsiWI, BspEI, BssSI, BstXI, BstZ17I, Bsu36I, BtrI, Eam1105I, Eco31I, Eco47III, Eco57I, EcoRI, EcoRV, FseI, FspAI, FspI, HpaI, I-CeuI, I-PpoI, I-SceI, KflI, KpnI, MauBI, MluI, MreI, NarI, NcoI, NheI, NmeAIII, OliI, PI-PspI, PI-SceI, PasI, PfoI, PmaCI, PmeI, PsrI, PstI, PvuII, RsrII, SacI, SapI, ScaI, SexAI, SgrAI, SgrDI, SphI, SrfI, Sse8387I, Tth111I.

---

# Experimental Procedures

---

## Working with fADL-1e

---

---

### General Molecular Biology Techniques

---

Molecular cloning and phage display should be conducted under the supervision of a qualified instructor trained to standard safety practice in a molecular biology laboratory environment. Standard molecular biology procedures can be found in a general molecular biology handbook such as Sambrook (1989).

---

---

### Working with Filamentous Phage

---

Keep the bench clean and regularly wiped with 2% bleach to limit phage cross-contamination and only use filtered tips to prevent aerosol contaminations. Phages are known to survive standard autoclaving conditions and are not removed by 0.22 µm filtration. Phages are either killed by heat-treating dry, autoclaved materials in an oven for 4 hours at 105°C (Phage Display 2001) or by incubation in 2% bleach for at least 1 hour. We recommend to extensively wash with hot water all glass and plastic-ware, then submerge (tubes) or incubate (flasks) with a 2% solution of bleach for at least one hour. Heat-resistant glassware can then be autoclaved in an autoclave that is never used for biological waste while sensitive plastic-ware can be used directly or at best heat-treated as described above.

---

---

### Bacterial Strains

---

In theory, any K12 F<sup>+</sup> *E. coli* strain is suitable for phage display using fADL-1e. Practically we recommend the strain SS320 with which fADL-1e gives large colonies. SS320 which has been widely used for phage display, is well-documented in the literature and has been extensively tested with fADL-1e. SS320 derives from MC1061 by introduction of a tet<sup>R</sup> F' episome (Sidhu 2000). Like most derivatives of MC1061, SS320 can be made highly competent for transformation by electroporation. We also recommend using the parent strain MC1061 for building libraries to limit contaminations by exogenous filamentous bacteriophage in original library stocks.

MC1061 and SS320 phenotypes are highlighted below:

**SS320** *hsdR2 mcrA0 araD139 Δ(araA-leu)7697 ΔlacX74 galK16 galE15(GalS) λe14<sup>-</sup> rpsL150(Str<sup>R</sup>) spoT1 thi*  
*F'[proAB+lacIqlacZΔM15 Tn10 (tet<sup>r</sup>)]*

**MC1061** *F hsdR2 mcrA0 araD139 Δ(araA-leu)7697 ΔlacX74 galK16 galE15(GalS) λe14<sup>-</sup> rpsL150(Str<sup>R</sup>) spoT1 thi*

---

---

### Plasmid Maintenance

---

Propagation and maintenance of fADL-1e is obtained on any F<sup>+</sup>, *recA1*, *endA1* *E. coli* strain using kanamycin 50 µg/ml as a selection marker. The use of an F<sup>+</sup> male strain may select for in-frame mutants that can take over the bacterial culture. We routinely isolate fADL-1e RF dsDNA using DH10B™ from Life Technologies with yields up to 2 mg/l and more.

---



---

## Cloning into fADL-1e

---

### Primer Design and PelB Leader Sequence

A complete PelB leader sequence *MKYLLPTAAAGLLLLAAQPAMA* is necessary for export in the periplasm and proper removal of the leader peptide by host proteases. In the following schema, where [NNN] represents the insert sequence and [Xxx] the translated amino acid sequence, the short hexanucleotide ATGGCN must be appended immediately to the first *SfiI* site to obtain a complete PelB leader encoding sequence; cleavage will occur on the C-terminal side of the terminal alanine (codon GCN):



### Cloning in fADL-1e Using *SfiI*/*BglII* Sites

Large libraries in the  $1 \times 10^9$  range and above can easily be constructed using the double *BglII*/*SfiI* cloning site.

The *SfiI* restriction enzyme recognizes rare 8-base-long interrupted palindromes GGCCNNNN/NGGCC and leaves 3-nucleotide-long overhangs after digestion. The fADL-1e cloning site contains one *SfiI* site close to the end of the PelB leader sequence and a second *SfiI* site 8 nucleotides apart from the first site. The PelB sequence of the empty vector has an early termination by an ochre stop codon and no gene III protein is produced by the vector alone.

The *SfiI* restriction enzyme requires two copies of its recognition sequence for cleavage to occur; cleavage of the two sites happens simultaneously through interaction of two *SfiI* tetramers (Wertzell 1995). Vectors bearing two sites very close to each other are cut in trans and digestion might not complete. Therefore we strongly recommend opening fADL-1e with the alternative *BglII* restriction enzyme, which cuts the shorter 6-base-long interrupted palindromes GCCNNNN/NGGC and generates identical overhangs.

Sites open with *BglII* will re-ligate with sites open with *SfiI* as long as overhangs are complementary. Practically, the pentanucleotide NNNNN must be identical to the original vector sequence to handle both ligation of the complementary overhangs and conservation of the amino acid sequence (PelB sequence and linker to protein III).

#### PREPARATION OF VECTOR DNA FOR CLONING

1. On ice add successively water, *BglII* buffer (1x final), fADL-1e vector and *BglII* enzyme 5 units/ $\mu$ g DNA; make sure the enzyme volume does not to exceed 1/10 of the total reaction volume.
2. Incubate 4 h to overnight at 37°C.
3. Inactivate for 20 min at 70°C.
4. Confirm the digestion by DNA analysis on a minigel.
5. Purify the cut vector.

---

For routine cloning, a standard DNA purification kit can be used directly after the digestion to remove the excess of buffer, the small DNA stuffer and leftover restriction enzyme. For library construction, phenol/chloroform extraction and/or gel purification may be required.

#### PREPARATION OF INSERTS

*SfiI* digestion should be rapid and complete in 4 hours especially for fragments longer or equal to 200 bp where sites are cut in *cis*. *BglI* may be used when the insert sequence is known to be free of *BglI* site and therefore is not recommended for building antibody libraries.

---

## Sequencing of Inserts

---

The following primers give both strong PCR amplification and sequencing traces.

#### Forward or Sense Primers

**phi8S3**            5'- CAAGCTGTTTAAGAAATTCACCTCG

**phiS2**            5'-ATGAAATACCTATTGCCTACGG

#### Backward, Antisense or Reverse Primers

**psiR2**            5'-CGTTAGTAAATGAATTTTCTGTATGAGG

**psiR3**            5'-GCGTAACGATCTAAAGTTTTGTCG

#### Nested Sequencing

Often it is easier to sequence an insert by PCR on the bacterial culture supernatant or directly from a colony rather than on tediously isolated plasmids. Use the outward primers phi8S3 and psiR3 together with a DNA polymerase not inhibited by bacterial cultures such as TAQ polymerase for the PCR and sequence the insert with the nested reverse primer psiR2. Use less than 1 µl of bacterial culture supernatant per 50 µl-PCR reaction or the touch of a toothpick on a colony as DNA template.

---

## Counting & Amplifying fADL-1e Virions

---

#### Preparation of bacterial cells

1. Peak a single colony from a SS320 agar plate supplemented with tetracycline 20 µg/ml and inoculate a 3-ml culture of 2xYT medium.
2. Incubate overnight at 37°C with agitation at 250 rpm.
3. Dilute an aliquot of the culture 1:10 v/v with fresh 2xYT medium in a new culture tube and incubate for one hour at 37°C with agitation at 250 rpm.
4. Take a small aliquot in sterile conditions and measure the absorbance at 600 nm of a 1:10 dilution in 2xYT medium ( $A_{600}$ ). Absorbance corrected for dilution should be between 0.5 OD and 1.0 OD and cells are ready to be transduced. If necessary adjust the length of incubation to your conditions.
5. Keep the cells at room temperature on the bench and proceed to the transduction within the hour.

---

## Transduction step

1. Dilute the phage with TBS is necessary.
2. Mix gently an aliquot of the phage dilution with an equal volume or more of bacterial culture.
3. Incubate at 37°C with agitation at 250 rpm for 30 min.
4. Dilute the culture if necessary with fresh 2xYT medium.
5. Plate immediately on 2xYT/agar plates supplemented with kanamycin 50 µg/ml and incubate o/n at 37°C.
6. In parallel add kanamycin 50 µg/ml final to the culture and pursue the incubation o/n at 37°C to amplify the phage if necessary.

## Counting transducing units (TU)

The day after count the number of colonies, adjust for dilution and express the results indistinctively as either cfu/ml (colony forming unit) or TU/ml (transducing unit). If you know the infectivity of your virions (normally around 5% for small peptide inserts but sometimes much lower for larger inserts), you can deduce the number of virion particles per ml (v/ml) and verify retrospectively than your multiplicity of infection (MOI) at the time of transduction was less than 0.1 (less than one virion particle per 10 bacteria) counting  $1.4E9$  bacteria/ml at  $A_{600}$  of 1.0 OD.

Systematically add controls to your experiments. Plating the bacterial culture on a plate supplemented with kanamycin 50 µg/ml will insure the absence of contamination by one of your phage prior to transduction; plating dilutions of the bacterial culture will count bacteria and help measure the MOI at the time of transduction. Finally always plate in duplicate and repeat the experiment on a different day with a new batch of bacteria and new phage dilutions for accuracy.

---

## Working with fADL-1e Virions

### Phage Production

The phage vector fADL-1e does not require a helper phage to produce virions. Cultures can be seeded directly from colonies obtained on kanamycin plates. For optimal conditions of growth and virion production, we recommend a rich medium such as 2xYT medium supplemented with kanamycin 50 µg/ml; incubate overnight at 37°C and 250 rpm.

### Phage Purification

For most applications, including screening of phage libraries, a single PEG precipitation is sufficient as a purification step. Please, consult **Antibody Design Labs** online technical resources at <http://www.abdesignlabs.com/technical-resources/> for a purification protocol using PEG precipitation. Sometime, especially when working with large libraries, a second PEG precipitation is indicated to achieve concentrated phage preparations. Note that multiple steps of PEG precipitation will be useful for concentration purposes but will unlikely improve purity; other purification methods beyond the scope of this manual such as purification over a cesium chloride gradient may be necessary. Phages are usually re-suspended in TBS or in PBS; conservatives are not necessary.

### Phage Quantification

The two main methods to quantify phages are transduction and spectrophotometry.

Transduction is a functional assay that measures a number of transducing units and is the recommended method to follow a biopanning experiment (the number of eluted TU normally increased rapidly when selection occurs). A detailed protocol is given in the above paragraph [Counting & Amplifying fADL-1e Virions](#).

---

Since virions are exclusively made of protein and DNA in a precise ratio, a formula has been devised to convert U.V spectrophotometry absorption readings into virion concentrations. Please, consult **Antibody Design Labs** online technical resources at <http://www.abdesignlabs.com/technical-resources/> for a protocol for phage concentration determination using spectrophotometry. Using this method, phage concentrations can be expressed in OD using  $A_{269-320}$  data. Spectrophotometry is the recommend method to quantify purified phages. For most phages a 10x concentration factor is sufficient during purification; some clones that do not produce a lot of virions may require a 20x or more concentration factor to yield phage concentrated enough for assay purpose. Note that below 0.1 OD (as equivalent phage OD taken in the original bacterial culture), results are usually biased and the concentration of phages is most likely overestimated.

## Storage

Phage are extremely resistant particles that will survive almost indefinitely once frozen. On the other hand, peptides and large inserts are more fragile and should not be stored more than a few days in the original culture supernatant at 4°C, or immediately frozen after purification and stored up to a few weeks at -20°C or at -80°C for longer term storage.

Phage preparations can be frozen directly without conservative although some people recommend adding 10% or 15% v/v glycerol. In our hands, in absence of glycerol, TU determination can tolerate up to 2 freeze-thaw cycles and binding assays such as ELISA and Western blots up to 4 freeze-thaw cycles without apparent changes. We normally aliquot libraries and store them at -80°C for an undetermined period of time and thaw them only once. Beyond those limits, we recommend adding glycerol 10% to the phage preparations.

## Contaminations

The possibility of contaminations by other phages, wild-type filamentous phages, helper phages or even fADL-1e phages from another library should always be in mind. Two reasons favor contaminations; first fd-tet-derived vectors are relatively constrained and make stable superinfections with other phages, in particular ubiquitous wild-type filamentous phage; second contaminations are easily transmitted along successive rounds of screen.

The best treatment of contamination is prevention. Follow precisely the [guidelines for working with phages](#) to keep contaminations away; separate vessels and plasticware using other phage systems from the one using fADL-1e vector; always use an F' strain such as MC1061 to build the primary libraries.

Sometimes deeper analyses are necessary to diagnostic a contamination. You can try to make plaques with your phage preparation (fADL-1e makes tiny plaques) or you can prepare RF DNA on an F' recA1 bacterial strain and analyze dsDNA. We find simpler to analyze circular ssDNA from purified phage preparation to verify for the absence of contamination. Please, consult **Antibody Design Labs** online technical resources at <http://www.abdesignlabs.com/technical-resources/> for a protocol for analyzing filamentous phage ssDNA by electrophoresis.

## Biopanning

---

Examples of screening workflows and biopanning strategies are illustrated in the MIM™ Phage Display Libraries instruction manual, see product AL101 and AL103.

---

# Appendix

---

## MSDS Information

---

MSDSs (Material Safety Data Sheets) are available on the **Antibody Design Labs** website at the corresponding product page.

---

## Quality Control

---

Specifications and quality control are detailed on the online product page. **Antibody Design Labs** certifies that the product will perform according to these specifications.

---

## Technical Support

---

Visit **Antibody Design Labs'** website at [www.abdesignlabs.com](http://www.abdesignlabs.com) for technical resources, including manuals, vector maps and sequences, application notes, FAQs, etc.

For more information or technical assistance, call, write, fax, or email us at:

**Antibody Design Labs**

4901 Morena Blvd, Suite 203  
San Diego, CA 92117

Phone: 1-877-223-3104 (TOLL-FREE)

Fax: 1-858-272-6007 (24 hour)

(Monday – Friday 9:00 AM – 5:00 PM PST)

Email: [support@abdesignlabs.com](mailto:support@abdesignlabs.com)

---

## References

---

1. SMITH, G. P., & PETRENKO, V. A. (1997). PHAGE DISPLAY. *CHEMICAL REVIEWS*, 97(2), 391–410.
2. ZACHER 3RD, A. N., STOCK, C. A., GOLDEN 2ND, J. W., & SMITH, G. P. (1980). A NEW FILAMENTOUS PHAGE CLONING VECTOR: FD-TET. *GENE*, 9(1-2), 127–140.
3. SAMBROOK, J., FRITSCH, E.F., AND MANIATIS, T. (1989). IN MOLECULAR CLONING: A LABORATORY MANUAL. COLD SPRING HARBOR LABORATORY PRESS, NY, VOL. 1, 2, 3.
4. PHAGE DISPLAY: A LABORATORY MANUAL (2001). EDITED BY C. F. BARBAS III, D. R. BURTON, J. K. SCOTT, AND G. J. SILVERMAN. COLD SPRING HARBOR, LABORATORY PRESS, COLD SPRING HARBOR, NY.
5. SIDHU SS, LOWMAN HB, CUNNINGHAM BC, WELLS JA (2000). PHAGE DISPLAY FOR SELECTION OF NOVEL BINDING PEPTIDES. *METHODS ENZYMOL*.328:333-63.
6. WERTZELL L.M. ET AL., (1995). THE SFII RESTRICTION ENDONUCLEASE MAKES A FOUR-STRAND DNA BREAK AT TWO COPIES OF ITS RECOGNITION SEQUENCE. *J. MOL. BIOL*. 248:581-595

*This product is subject to Antibody Design Labs Terms & Conditions of Sales available online at <http://www.abdesignlabs.com/terms/>.*

*© 2021 Antibody Design Labs. All rights reserved.*

---